CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $4,772,310 | +366.5% | 117,400 | +769.6% | 0.69% | +3181.0% |
| Q4 2021 | $1,023,000 | -82.3% | 13,500 | -73.8% | 0.02% | -88.0% |
| Q3 2021 | $5,764,000 | -42.5% | 51,500 | -16.8% | 0.18% | -50.8% |
| Q2 2021 | $10,021,000 | -73.5% | 61,900 | -80.1% | 0.36% | -62.4% |
| Q1 2021 | $37,883,000 | +302.3% | 310,900 | +405.5% | 0.95% | +428.5% |
| Q4 2020 | $9,416,000 | +34.9% | 61,500 | -35.3% | 0.18% | -62.9% |
| Q2 2020 | $6,981,000 | – | 95,000 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |